Identifying Novel Targets for Non-Small Cell Lung Cancer – Just How Novel Are They?

Despite significant advances in the treatment of lung cancer, this disease continues to be the leading cause of cancer death among men and the second leading cause among women, worldwide. In the European Union alone, approximately 191,900 men and 87,500 women were expected to die of lung cancer in 2015 (age-standardized mortality rate 35.98 and 14.24 per 100,000 in men and women, respectively). In the absence of curative therapies, the objectives of lung cancer treatment are prolongation of survival and the achievement and maintenance of a good quality of life for as long as possible. While this has led to numerous treatments coming to market over the years including surgery, radiotherapy, chemotherapy, immunotherapy or any combination thereof, it leaves an opportunity to develop new treatments that build on past findings and continuously improve the range of outcomes for potential patients.

Unfortunately, many scientists struggle when it comes to compiling research conducted on previous targets, leading them to continue down pathways that have already been proven to be ineffective. This is why being able to efficiently identify and prioritize novel targets for all diseases, and especially lung cancer, has become an increasingly important step in the drug development process.

In this webinar, featured speakers will demonstrate new ways in which publicly available non-small-cell lung cancer (NSCLC) datasets can be examined in order to find novel approaches to targeting the disease. Specifically, they will discuss how quick and easy it can be (with the right tools) to examine the novelty of your target and the importance of doing so. In the end, the speakers will use these tools to find evidence for core known tumour suppressive mechanisms to be potential targets for NSCLC.

What you will learn:

• The latest trends in lung cancer research
• New techniques for identifying targets, specifically using gene expression analysis
• How you can prioritize targets for cancer research more efficiently

Speakers

Alexey Dubovenko, Discovery Solutions Product Manager, Clarivate Analytics

Alexey graduated from the School of Bioengineering and Bioinformatics at Moscow State University. Over the last 10 years he has worked in biological data analysis including the biological interpretation of OMICs data in different therapeutic areas, personalized treatment selection in oncology, mathematical modeling of treatment efficacy, toxicity, pharmacokinetics and pharmacodynamics on preclinical and clinical phases for top pharmaceutical companies. Alexey became the Discovery Sciences Product Manager at Clarivate Analytics in 2015.

Message Presenter

Sonya Novikova, Solution Scientist, Life Sciences, Clarivate Analytics

Sonya Novikova is the Solution Scientist in Discovery and Preclinical Research, Life Sciences, at Clarivate Analytics. In her role, she searches for solutions to address customers’ needs in early drug and biomarker discovery and preclinical research. Sonya has over 10 years of experience in the life sciences industry, having extensive knowledge of molecular signaling pathways & networks, OMICs data analysis and interpretation, and disease mechanisms reconstruction.

Message Presenter